Carnyx Therapeutics Unveils Oral Sleep Candidate CNYX-005 with Preclinical Data Showing Increased NREM Sleep
Preclinical study shows 1.5- to 2-hour increase in total sleep time as Company advances toward clinical development and attracts Chris Brearley, M.D., as Chief Medical Officer INDIANAPOLIS, Oct. 14, 2026 /PRNewswire/ -- Carnyx Therapeutics Ltd. ("Carnyx" or the "Company"), a...
Read the full story on PR Newswire → Opens the original article on www.prnewswire.comSummary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.